Halozyme Therapeutics Inc (HALO)
Solvency ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 5.67 | 4.68 | 6.80 | 10.36 | 20.68 | 7.60 | 11.99 | 25.81 | 10.85 | 19.22 | 6.08 | 4.47 | 5.61 | 4.21 | 8.57 | 14.30 | 3.84 | 5.29 | 4.99 | 8.48 |
Halozyme Therapeutics Inc's solvency ratios paint a positive picture, as indicated by consistently low values across various metrics. The Debt-to-assets ratio, Debt-to-capital ratio, and Debt-to-equity ratio have all been consistently reported as 0.00 from March 31, 2020, up to December 31, 2024. This signifies that the company has not relied heavily on debt to finance its operations and has maintained a strong solvency position.
Additionally, the Financial leverage ratio, which is a measure of the company's debt relative to its equity, has shown fluctuations over the years. The ratio was relatively high in March 31, 2020, at 8.48, but decreased significantly in the subsequent quarters, indicating a reduction in financial leverage. However, there were fluctuations in the ratio over the years, reaching peaks in March 31, 2023, and then decreasing again in the following quarters. Overall, the company's financial leverage has not posed a significant risk to its solvency position.
In conclusion, based on the solvency ratios analyzed, Halozyme Therapeutics Inc appears to have a strong financial position with low debt levels and adequate capital structure, indicating a stable and sustainable solvency position.
Coverage ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | 31.24 | 26.04 | 22.68 | 21.67 | 19.57 | 18.55 | 14.73 | 12.49 | 15.66 | 17.11 | 27.85 | 41.21 | 36.77 | 28.38 | 19.18 | 11.83 | 7.34 | 2.13 | -1.46 | -4.82 |
Interest coverage is a financial ratio that measures a company's ability to meet its interest payments on outstanding debt. A higher interest coverage ratio indicates a company is more capable of servicing its debt obligations.
Analyzing Halozyme Therapeutics Inc's interest coverage ratio over the provided periods shows significant fluctuations. The company had negative interest coverage ratios in the first two quarters of 2020, indicating potential financial distress. However, the ratio improved rapidly throughout 2020 and continued to increase steadily throughout 2021, reflecting a strengthening ability to cover interest expenses.
By March 31, 2022, the interest coverage ratio reached a peak of 41.21, indicating ample capacity to cover interest payments. However, a subsequent decline in the ratio was observed by the end of June 2022 and continued into 2023. This decline may suggest a potential increase in interest expenses relative to operating income during this period.
Halozyme Therapeutics Inc experienced fluctuations in its interest coverage ratio beyond 2022, with ratios settling at levels between 14.73 and 31.24 by the end of 2024. It is worth noting that an interest coverage ratio above 1 indicates the company is generating enough earnings to cover interest payments, but a higher ratio suggests a stronger financial position.
Overall, while Halozyme Therapeutics Inc's interest coverage ratio has shown volatility, the company has generally demonstrated an improving ability to cover its interest expenses, with fluctuations in later years possibly indicating changing financial conditions or investment strategies. Further monitoring of this ratio would be necessary to assess the company's ongoing financial health.